Búsqueda | Biblioteca Virtual en Salud

1.

Single institution followed by national implementation of systematic surgical quality control and feedback for radical prostatectomy: a 20-year journey.

Stranne, J; Axen, E; Franck-Lissbrant, I; Fransson, P; Frånlund, M; Hugosson, J; Khatami, A; Koss-Modig, K; Lodding, P; Nyberg, M; Stattin, P; Bratt, O.

World J Urol ; 38(6): 1397-1411, 2020 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-31388817

2.

The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study.

Gnanapragasam, V J; Bratt, O; Muir, K; Lee, L S; Huang, H H; Stattin, P; Lophatananon, A.

BMC Med ; 16(1): 31, 2018 02 28.

Artículo en Inglés | MEDLINE | ID: mdl-29490658

3.

¹8F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer.

Kjölhede, H; Ahlgren, G; Almquist, H; Liedberg, F; Lyttkens, K; Ohlsson, T; Bratt, O.

World J Urol ; 32(4): 965-70, 2014 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-24141889

4.

Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer.

Bratt, O; Häggman, M; Ahlgren, G; Nordle, O; Björk, A; Damber, J-E.

Br J Cancer ; 101(8): 1233-40, 2009 Oct 20.

Artículo en Inglés | MEDLINE | ID: mdl-19755981

5.

The risk of malignant tumours in first-degree relatives of men with early onset prostate cancer: a population-based cohort study.

Bratt, O; Kristoffersson, U; Lundgren, R; Olsson, H.

Eur J Cancer ; 33(13): 2237-40, 1997 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-9470812

6.

Familial and hereditary prostate cancer in southern Sweden. A population-based case-control study.

Bratt, O; Kristoffersson, U; Lundgren, R; Olsson, H.

Eur J Cancer ; 35(2): 272-7, 1999 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-10448270

7.

Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer.

Bratt, O; Damber, J E; Emanuelsson, M; Kristoffersson, U; Lundgren, R; Olsson, H; Grönberg, H.

Eur J Cancer ; 36(2): 235-41, 2000 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-10741283

8.

Amplification of hypoxia-inducible factor 1alpha gene in prostate cancer.

Saramäki, O R; Savinainen, K J; Nupponen, N N; Bratt, O; Visakorpi, T.

Cancer Genet Cytogenet ; 128(1): 31-4, 2001 Jul 01.

Artículo en Inglés | MEDLINE | ID: mdl-11454426

9.

Sons of men with prostate cancer: their attitudes regarding possible inheritance of prostate cancer, screening, and genetic testing.

Bratt, O; Kristoffersson, U; Lundgren, R; Olsson, H.

Urology ; 50(3): 360-5, 1997 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-9301698

10.

Metaphase cytogenetics and DNA flow cytometry with analysis of S-phase fraction in prostate cancer: influence on prognosis.

Bratt, O; Anderson, H; Bak-Jensen, E; Baldetorp, B; Lundgren, R.

Urology ; 47(2): 218-24, 1996 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-8607238

11.

Hereditary prostate cancer

Bratt O.

BJU Int ; 85(5): 611-3, 2000 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-10735938

12.

[More humanities, but not chiefly theology!]. / Ge oss mer humaniora, men inte främst teologi!

Bratt, O.

Lakartidningen ; 97(28-29): 3298, 2000 Jul 12.

Artículo en Sueco | MEDLINE | ID: mdl-10997028

13.

[Localized prostatic cancer--should the patient or the physician choose the treatment?]. / Lokaliserad prostatacancer--ska patienten eller doktorn välja behandling?

Bratt, O.

Lakartidningen ; 97(41): 4632, 4634, 2000 Oct 11.

Artículo en Sueco | MEDLINE | ID: mdl-11107758

14.

[Symptomatic prostatic cancer must be treated!]. / Symtomgivande prostatacancer ska behandlas!

Bratt, O; Colleen, S.

Lakartidningen ; 93(26-27): 2494, 1996 Jun 26.

Artículo en Sueco | MEDLINE | ID: mdl-8684077

15.

[Research progress on hereditary prostatic cancer. Families at risk should be surveyed and screening should be offered]. / Forskningsframsteg om hereditär prostatacancer. Riskfamiljer bör kartläggas och erbjudas screening.

Bratt, O; Abrahamsson, P A; Lundgren, R; Olsson, H; Kristoffersson, U.

Lakartidningen ; 95(14): 1494-6, 1998 Apr 01.

Artículo en Sueco | MEDLINE | ID: mdl-9564131

16.

CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden.

Wagenius, M; Borg, A; Johansson, L; Giwercman, A; Bratt, O.

Scand J Urol Nephrol ; 40(1): 23-5, 2006.

Artículo en Inglés | MEDLINE | ID: mdl-16452051

17.

Morbidity of pelvic lymphadenectomy, radical retropubic prostatectomy and external radiotherapy in patients with localised prostatic cancer.

Bratt, O; Elfving, P; Flodgren, P; Lundgren, R.

Scand J Urol Nephrol ; 28(3): 265-71, 1994 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-7817168

18.

Hereditary prostate cancer: clinical characteristics and survival.

Bratt, O; Damber, J-E; Emanuelsson, M; Grönberg, H.

J Urol ; 167(6): 2423-6, 2002 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-11992050

19.

Clinical course of early onset prostate cancer with special reference to family history as a prognostic factor.

Bratt, O; Kristoffersson, U; Olsson, H; Lundgren, R.

Eur Urol ; 34(1): 19-24, 1998.

Artículo en Inglés | MEDLINE | ID: mdl-9676409

20.

CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk.

Bratt, O; Borg, A; Kristoffersson, U; Lundgren, R; Zhang, Q X; Olsson, H.

Br J Cancer ; 81(4): 672-6, 1999 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-10574254

Biblioteca Virtual en Salud

Hipertensión

Su selección (0)

Formato de exportación:

Exportar:

Single institution followed by national implementation of systematic surgical quality control and feedback for radical prostatectomy: a 20-year journey.

The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study.

¹8F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer.

Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer.

The risk of malignant tumours in first-degree relatives of men with early onset prostate cancer: a population-based cohort study.

Familial and hereditary prostate cancer in southern Sweden. A population-based case-control study.

Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer.

Amplification of hypoxia-inducible factor 1alpha gene in prostate cancer.

Sons of men with prostate cancer: their attitudes regarding possible inheritance of prostate cancer, screening, and genetic testing.

Metaphase cytogenetics and DNA flow cytometry with analysis of S-phase fraction in prostate cancer: influence on prognosis.

Hereditary prostate cancer

[More humanities, but not chiefly theology!]. / Ge oss mer humaniora, men inte främst teologi!

[Localized prostatic cancer--should the patient or the physician choose the treatment?]. / Lokaliserad prostatacancer--ska patienten eller doktorn välja behandling?

[Symptomatic prostatic cancer must be treated!]. / Symtomgivande prostatacancer ska behandlas!

[Research progress on hereditary prostatic cancer. Families at risk should be surveyed and screening should be offered]. / Forskningsframsteg om hereditär prostatacancer. Riskfamiljer bör kartläggas och erbjudas screening.

CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden.

Morbidity of pelvic lymphadenectomy, radical retropubic prostatectomy and external radiotherapy in patients with localised prostatic cancer.

Hereditary prostate cancer: clinical characteristics and survival.

Clinical course of early onset prostate cancer with special reference to family history as a prognostic factor.

CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk.